However, these methods are limited in the assessment of other cryptic rearrangements that were recently proposed for B-ALL, such as DUX4, EPOR, ZNF384 and MYC rearrangements, and single-point mutations (PAX P80R or IKZF1 N159Y) [30], as well as T-ALL subtypes defined by TAL-LMO or LYL1 in association with gene expression signatures [31,32]. The gene discussed is EPOR; the disease is acute lymphoblastic leukemia.